Repligen Corp. has completed an 11,000-sq.-ft. expansion of its U.S. manufacturing facility in Waltham, which now includes a dedicated space for the production and assembly of Repligen’s Alternating Tangential Flow System (ATF System), a recent addition to the company’s upstream bioprocessing product portfolio.
 
The ATF System is used to increase cell density and product yield during the fermentation step of the biologic drug manufacturing process. The expansion includes areas for ATF System assembly, quality control and inventory, as well as cleanroom suites for the production of single-use ATF Systems in an ISO 7 environment.
 
The facility upgrade also expands areas dedicated to cell culture R&D, as well as manufacturing and support of the company’s ELISA test kits and its OPUS line of pre-packed chromatography columns. An additional 7,500 sq.-ft. is reserved for future expansion.
 
“This expansion satisfies our goal to rapidly transfer ATF System operations, which we acquired from Refine Technology of Pine Brook, NJ in June 2014, to our Waltham facility. This new space is designed to meet the highest standards of quality and service that our customers expect from Repligen, and will improve lead times for product delivery,” said Walter C. Herlihy, Ph.D., retiring president and chief executive officer of Repligen.